Form 4: ALNYLAM Executive Boosts Stake with Service Award, 401(k) Shares

Alnylam Pharmaceuticals' CSO & EVP, Kevin Fitzgerald, increased his beneficial ownership through a 20-year service award and 401(k) matching contributions.

Summary

• Kevin Joseph Fitzgerald, CSO & EVP, Head of Research at Alnylam Pharmaceuticals, Inc. (ALNY), reported changes in his beneficial ownership.
• On February 23, 2026, he acquired 158 shares of common stock, which were approved by the People, Culture, and Compensation Committee as part of a 20-year continuous employment recognition award. These shares, net of minimum statutory tax liability, were issued on December 5, 2025.
• An additional 537 shares of common stock were acquired indirectly through the issuer's 401(k) plan due to matching contributions.
• Following these transactions, Fitzgerald directly owns 21,422 shares and indirectly owns 537 shares via a managed account.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, reflecting an executive's continued commitment to the company through a long-term service award and participation in employee benefit plans, which aligns management interests with shareholders.

Positives

• An insider (CSO & EVP) increased beneficial ownership of company stock.
• The acquisition of shares is tied to a long-term service award (20 years), indicating management stability and commitment.
• Additional shares were acquired through a 401(k) matching program, reflecting standard employee benefits.

Industry Context

StockSavvy.ai notes that insider ownership, particularly through long-term service awards and 401(k) plans, is a common practice in the biotechnology and pharmaceutical sectors to align executive interests with shareholder value and retain key talent.

Stakeholder Impact

• Shareholders: Increased insider ownership can be seen as a positive signal of confidence.
• Employees: The 20-year service award highlights the company's recognition of long-term employee contributions and retention efforts.

Key Dates

Recommendation

This Form 4 reports routine insider share acquisitions related to a long-term service award and 401(k) matching contributions. While it indicates continued executive commitment, it does not provide new fundamental information to alter an investment thesis, thus a 'hold' recommendation is appropriate for existing positions.

Keywords

Alnylam Pharmaceuticals, ALNY, Form 4, Insider Transaction, Stock Ownership, Executive Compensation, Kevin Fitzgerald, CSO, EVP, Research, Biotechnology, Pharmaceuticals